LifeScience Clinical & Diagnostic

Sichuan Kelun-Biotech Biopharmaceutical Secures China IND Clearance For PD 1 x VEGF Bispecific SKB118 In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...

 May 14, 2026 | News

Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the prelimina...

 May 13, 2026 | News

Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreement...

 May 13, 2026 | News

Chance Pharma Advances First NDA Submission In China For Innovative Asthma Therapy CXG87

Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhala...

 May 11, 2026 | News

Harbour BioMed Secures US FDA Clearance For Phase I Trial Of Bispecific Cancer Antibody HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

 May 11, 2026 | News

Mabwell Secures US FDA Clearance For First In Class Autoimmune Antibody 9MW5211

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigation...

 May 11, 2026 | News

Australia Registers PEDMARQSI As First Approved Therapy To Prevent Cisplatin Related Hearing Loss In Children

PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 ...

 May 07, 2026 | News

Alebund Completes Global Phase III Enrollment For AP301 In Hyperphosphatemia Trial

Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies...

 May 07, 2026 | News

Thermo Fisher Introduces Gibco CTS DynaXS Single Use Bioreactor For Scalable Cell Therapy Manufacturing

New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical productio...

 May 05, 2026 | News

EnGeneIC Doses First Patient In Trial Targeting Recurrent Glioblastoma

EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...

 May 05, 2026 | News

Cardioline Acquires Cardios To Expand Global Telecardiology And Diagnostic Capabilities

Strategic combination unites Cardioline’s global reach and proven cardiac technology with Cardios’s decades of clinical expertise in Holter m...

 May 05, 2026 | News

Restore Vision Reports Encouraging Phase I II Data For RV 001 Gene Therapy In Retinitis Pigmentosa

Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key Ma...

 May 04, 2026 | News

Lakewood Amedex Advances Nu 3 Bisphosphocin Candidate With Strong AMR Resistance Profile

Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins® Lakewood-Amedex Biotherapeutics Inc., (NASD...

 May 04, 2026 | News

Sonire Therapeutics Initiates SUNRISE II Trial To Advance Non Invasive HIFU Therapy For Pancreatic Cancer In The United States

SUNRISE-II feasibility trial marks the company's entry into U.S. clinical development, advancingminimally invasive, anesthesia-free treatment approach Son...

 May 04, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close